TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07715097: A Phase II Clinical Trial of Survivin-Targeted Dendritic Cell (DC) Injection for the Treatment of Newly DiagnosedGlioblastoma

Sponsor: Beijing Tricision Biotherapeutics Inc · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07715097 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07715097 Rescue Dossier →